Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ShA9 Topical Gel for Atopic Dermatitis
NCT06504160Phase 1Recruiting
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- May 2025
- Primary completion
- Dec 2026
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in atopic dermatitis (AD) comparing ShA9 Topical Gel with Placebo (Vehicle) Topical Gel (2 arms). Primary endpoints: Time to the first Atopic Dermatitis (AD) flare at 14 weeks and Treatment-emergent adverse events at 18 weeks. Started May 2025; status: recruiting.
02
Drugs
Staphylococcus hominis A9
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT06504160.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06504160.